Calquence Side Effects
Generic name: acalabrutinib
Medically reviewed by Drugs.com. Last updated on Apr 14, 2022.
Note: This document contains side effect information about acalabrutinib. Some of the dosage forms listed on this page may not apply to the brand name Calquence.
For the Consumer
Applies to acalabrutinib: oral capsule
Side effects requiring immediate medical attention
Along with its needed effects, acalabrutinib (the active ingredient contained in Calquence) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking acalabrutinib:
More common
- Bleeding gums
- collection of blood under the skin
- coughing up blood
- difficulty in breathing or swallowing
- dizziness
- headache
- increased menstrual flow or vaginal bleeding
- itching, pain, redness, or swelling
- large, flat, blue or purplish patches in the skin
- nosebleeds
- paralysis
- prolonged bleeding from cuts
- red or black, tarry stools
- red or dark brown urine
Side effects not requiring immediate medical attention
Some side effects of acalabrutinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Constipation
- diarrhea
- difficulty in moving
- joint pain or swelling
- muscle cramp, pain, or stiffness
- nausea
- rash
- stomach pain
- unusual tiredness or weakness
- vomiting
For Healthcare Professionals
Applies to acalabrutinib: oral capsule
General
The most common adverse reactions (reported incidence of 20% or greater) were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising.[Ref]
Cardiovascular
Very common (10% or more): Bleeding events (50%)
Common (1% to 10%): Hemorrhage/hematoma
Uncommon (0.1% to 1%): Atrial fibrillation, atrial flutter[Ref]
Hematologic
Very common (10% or more): Decreased hemoglobin (46%), decreased platelets (44%), decreased neutrophils (36%), neutropenia (23%), anemia (11%)
Common (1% to 10%): Thrombocytopenia[Ref]
Nervous system
Very common (10% or more): Headache (39%)[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (31%), nausea (19%), abdominal pain (15%), constipation (15%), vomiting (13%)[Ref]
Dermatologic
Very common (10% or more): Bruising/petechiae/ecchymosis/contusion (21%), rash (18%)[Ref]
Musculoskeletal
Very common (10% or more): Myalgia (21%)[Ref]
Oncologic
Very common (10% or more): Second primary malignancies (11%)
Common (1% to 10%): Skin cancer[Ref]
Hepatic
Common (1% to 10%): Increased creatinine[Ref]
Respiratory
Common (1% to 10%): Epistaxis
Frequency not reported: Pneumonia[Ref]
Other
Very common (10% or more): Fatigue (28%)
Frequency not reported: Infections[Ref]
Frequently asked questions
More about Calquence (acalabrutinib)
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (1)
- Drug images
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: BTK inhibitors
- FDA approval history
Patient resources
Professional resources
Related treatment guides
References
1. "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.